⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL114436 | 1.00 | — | — | |
| SCHEMBL28504938 | 0.87 | CYP11B1 (0.37) | — | |
| SCHEMBL10434697 | 0.80 | KDM4E (0.34) | — | |
| Methanesulfonic Acid Methyl Ester SCHEMBL28827049 | 0.80 | USP2 (0.36) | — | |
| SCHEMBL31285235 | 0.79 | CES2 (0.38) | — | |
| SCHEMBL2783567 | 0.79 | CES2 (0.38) | — | |
| SCHEMBL28870 | 0.78 | HDAC8 (0.36) | — | |
| SCHEMBL29549283 | 0.78 | HDAC8 (0.36) | — | |
| SCHEMBL28351566 | 0.77 | ALDH1A1 (0.41) | — | |
| SCHEMBL29251289 | 0.77 | GRM5 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720067-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | Recursion Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4580620-A2 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS, COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | Hager Biosciences, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024246559-A1 | BICYCLIC HETEROARYLAMIDES HAVING GPR68 MODULATING ACTIVITY | EXSCIENTIA AI LIMITED (GB) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024216167-A1 | COMPOSITIONS COMPRISING MODULATORS OF RIBONUCLEOPROTEIN GRANULE FORMATION AND DISSOLUTION AND METHODS OF USE THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2024166024-A1 | NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2024-08-15 | — | — | WO | disclosed |
| WO-2024050061-A2 | PYRAZOLE AND IMIDAZOLE DERIVATIVES AS DUAL OREXIN AND KAPPA-OPIOID RECEPTORS MODULATORS, COMPOSITION, METHODS FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | HAGER BIOSCIENCES, LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| EP-4157898-A1 | CHEMICALLY CONVERTED CATALYSTS | Dow Global Technologies LLC (US) | 2023-04-05 | — | — | EP | disclosed |
| EP-4110777-A1 | PYRROLOPYRIDINE AND IMIDAZOPYRIDINE ANTIVIRAL COMPOUNDS | Katholieke Universiteit Leuven, K.U.Leuven R&D (BE) | 2023-01-04 | — | — | EP | disclosed |
| EP-3997247-A1 | METHODS FOR USE OF GENE EXPRESSION AS AN INDICATOR OF E-SELECTIN INHIBITOR EFFICACY AND CLINICAL OUTCOME FOR MULTIPLE TUMOR TYPES | GlycoMimetics, Inc. (US) | 2022-05-18 | — | — | EP | disclosed |
| EP-3958978-A1 | GALACTOSE-LINKED MULTIMERIC GLYCOMIMETIC INHIBITORS OF E-SELECTINS, GALECTIN-3, AND/OR CXCR4 CHEMOKINE RECEPTORS | GlycoMimetics, Inc. (US) | 2022-03-02 | — | — | EP | disclosed |